Pharmac have released public consultation on a proposal to widen access to funded multiple sclerosis treatments and transition access from the Multiple Sclerosis Treatment Assessment Committee (MSTAC) Panel to a…read more
These webinars cover the latest in MS research. Highlights include Dr Wallace Brownlee, who dialled in from London to update us on HSCT treatments for MS, and Justin O’Sullivan speaking…read more
New data on the long term benefits of Ocrelizumab for PPMS has recently been published 29 October 2020 on the Lancet Ocrelizumab is currently funded for RRMS in New Zealand…read more
Note: This article was originally published on www.multiplesclerosisnewstoday.com, written by Marta Figueiredo and fact checked by Patrícia Silva, PHD. MD1003, MedDay Pharmaceuticals’ high-dose biotin therapy, failed to significantly improve functional…read more
A survey exploring participants’ perspectives of people living with Multiple Sclerosis to better understand adjustment to diagnosis and the role of psychological support in the patient journey.read more
Exploring patterns of medicinal cannabis use prior to implementation of the new Medicinal Cannabis Scheme (MCS) in New Zealand.read more
Questionnaire for persons with multiple sclerosis: language, communication, and quality of liferead more
Positive psychological health and self-compassion are important for positive outcomes for people with MS and protect them against poorer outcomes.read more
You are invited to take part in a study, exploring your views on the value of a telehealth complex-wheelchair assessment service.read more
PROMS comes to another key milestone on the road to its mission, announcing members of the Executive Committee and Scientific Steering Committee.read more
The latest developments in MS research streamed live.read more
Join us to hear about the latest development in MS research happening nationally and internationally.read more
ECTRIMS launch for new patient-centred initiativeread more
Exciting new resultsread more
Special issue of Neurology Research Review, focusing specifically on MS.read more
One of the known risk factors of developing MS but how EBV relates to MS risk is still an open question.read more
Substantially increased since 1990, according to study results published in Lancet Neurology.read more
Low vitamin D has long been a risk factor for developing MS, but how does that tie in with MS risk genes?read more
What do the MS treatments ocrelizumab, alemetuzumab and natalizumab (Ocrevus, Lemtrada, and Tysabri) have in common?read more
